Subject: Specialty Quantity Limit Zeposia 4775-H P2023

Drug

ZEPOSIA  (ozanimod)

Policy:

I.  PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.


II.  COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Zeposia (ozanimod)   7-Day Starter Pack   (four 0.23 mg capsules   and three 0.46 mg capsules)	1 Starter Pack   (7 capsules) per 7 days	Multiple Sclerosis and Ulcerative Colitis   •   Treatment initiation:        º  Days 1-4: 0.23 mg daily        º  Days 5-7: 0.46 mg daily   •    Maintenance dose: 0.92 mg daily starting on         day 8
Zeposia (ozanimod) (37-day)   Starter Kit   (one 7-Day Starter Pack and   one bottle of thirty 0.92 mg   capsules)	1 Starter Kit   (37 capsules) per 37 days
Zeposia (ozanimod) (28-day)   Starter Kit   (one 7-Day Starter Pack and   twenty-one 0.92 mg capsules)	1 Starter Kit (28   capsules) per 28 days
Zeposia (ozanimod)   0.92 mg capsules	30 capsules per 30 days

 

 

Place of Service:

Outpatient

The above policy is based on the following references:

1. Zeposia [package insert]. Princeton, NJ: Bristol-Meyers Squibb Company; April 2023.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

December 09, 2023